NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free TARS Stock Alerts $36.35 +1.78 (+5.15%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$34.24▼$37.1650-Day Range$22.84▼$39.2252-Week Range$11.33▼$40.40Volume1.03 million shsAverage Volume783,347 shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$48.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tarsus Pharmaceuticals alerts: Email Address Tarsus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside31.1% Upside$48.38 Price TargetShort InterestBearish21.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 4 Articles This WeekInsider TradingSelling Shares$749,578 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.59) to ($2.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.47 out of 5 starsMedical Sector409th out of 938 stocksBiological Products, Except Diagnostic Industry61st out of 154 stocks 4.4 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.38, Tarsus Pharmaceuticals has a forecasted upside of 31.1% from its current price of $36.89.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.04% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 19.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 3.3 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for TARS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows7 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $749,578.00 in company stock.Percentage Held by Insiders11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.59) to ($2.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -7.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -7.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More TARS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARS Stock News HeadlinesMarch 20, 2024 | insidertrades.comBryan Wahl Sells 4,436 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 24, 2024 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 21, 2024 | investing.comTarsus Pharmaceuticals executive sells over $130k in company stockMarch 21, 2024 | investing.comTarsus Pharmaceuticals exec sells over $135k in stockMarch 20, 2024 | americanbankingnews.comInsider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 10,415 Shares of StockMarch 18, 2024 | msn.comPill Targeting Tick-Induced Lyme Disease Shows Promise in Human TrialsMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 25.000 callMarch 28, 2024 | DTI (Ad)How you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! March 16, 2024 | finance.yahoo.comTARS Apr 2024 17.500 putMarch 16, 2024 | finance.yahoo.comTARS Apr 2024 12.500 callMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)March 5, 2024 | globenewswire.comTarsus to Participate at Upcoming Investor ConferencesMarch 5, 2024 | globenewswire.comTarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisMarch 2, 2024 | investing.comTarsus Pharmaceuticals launches $100 million stock offeringMarch 1, 2024 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their EstimatesMarch 1, 2024 | msn.comTarsus Pharmaceuticals stock dips after pricing $100M securities offeringMarch 1, 2024 | marketwatch.comTarsus Pharmaceuticals Shares Slip Premarket After Stock OfferingMarch 1, 2024 | globenewswire.comTarsus Announces Pricing of $100.0 Million Public OfferingFebruary 29, 2024 | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketwatch.comTarsus Pharmaceuticals Shares Fall 11% After Public Offering NewsFebruary 29, 2024 | msn.comTarsus announces proposed $100M public offeringFebruary 29, 2024 | globenewswire.comTarsus Announces Proposed $100.0 Million Public OfferingFebruary 29, 2024 | finance.yahoo.comParty Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings ForecastsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed: Tarsus Pharmaceuticals’ Strong Q4 and Robust Pipeline Fuel Upward Price RevisionFebruary 28, 2024 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comTarsus Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsSee More Headlines Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees244Year FoundedN/APrice Target and Rating Average Stock Price Target$48.38 High Stock Price Target$59.00 Low Stock Price Target$30.00 Potential Upside/Downside+33.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,890,000.00 Net MarginsN/A Pretax Margin-778.89% Return on Equity-74.28% Return on Assets-58.20% Debt Debt-to-Equity Ratio0.15 Current Ratio6.93 Quick Ratio6.85 Sales & Book Value Annual Sales$17.45 million Price / Sales71.29 Cash FlowN/A Price / Cash FlowN/A Book Value$5.95 per share Price / Book6.11Miscellaneous Outstanding Shares34,219,000Free Float30,270,000Market Cap$1.24 billion OptionableOptionable Beta1.07 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanDr. Bryan Wahl J.D. (Age 46)M.D., General Counsel & Corporate Secretary Comp: $619.09kDr. Elizabeth Yeu Lin M.D. (Age 46)Chief Medical Advisor & Director Comp: $286kMr. Jeffrey S. Farrow (Age 62)CFO & Chief Strategy Officer Dr. Seshadri Neervannan Ph.D. (Age 56)Chief Operating Officer Comp: $486.67kMr. David NakasoneHead of Investor RelationsMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMs. Dianne C. Whitfield M.S.W. (Age 47)Chief Human Resources Officer Comp: $578.9kMore ExecutivesKey CompetitorsScholar RockNASDAQ:SRRKBioCryst PharmaceuticalsNASDAQ:BCRXKyverna TherapeuticsNASDAQ:KYTXRelay TherapeuticsNASDAQ:RLAYVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsSeshadri NeervannanSold 4,879 sharesTotal: $149,297.40 ($30.60/share)Aziz MottiwalaSold 4,766 sharesTotal: $145,839.60 ($30.60/share)Bryan WahlSold 4,436 sharesTotal: $135,741.60 ($30.60/share)Bobak R AzamianSold 10,415 sharesTotal: $318,699.00 ($30.60/share)Vanguard Group Inc.Bought 43,699 shares on 3/11/2024Ownership: 4.662%View All Insider TransactionsView All Institutional Transactions TARS Stock Analysis - Frequently Asked Questions Should I buy or sell Tarsus Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks. What is Tarsus Pharmaceuticals' stock price target for 2024? 8 analysts have issued 12 month price targets for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $30.00 to $59.00. On average, they predict the company's stock price to reach $48.38 in the next twelve months. This suggests a possible upside of 31.1% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts. How have TARS shares performed in 2024? Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of 2024. Since then, TARS shares have increased by 82.2% and is now trading at $36.89. View the best growth stocks for 2024 here. When is Tarsus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our TARS earnings forecast. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.06. The business earned $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same quarter in the prior year, the company posted ($0.49) earnings per share. What ETF holds Tarsus Pharmaceuticals' stock? Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (9.52%), Vivo Capital LLC (5.39%), Vanguard Group Inc. (4.82%), Vanguard Group Inc. (4.66%), TFG Asset Management GP Ltd (2.42%) and Dimensional Fund Advisors LP (1.30%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TARS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.